Open AccessLocalization of MCT 2 at peroxisomes is associated with malignant transformation in prostate cancer
Author(s) -
Valença Isabel,
PértegaGomes Nelma,
Vizcaino José Rámon,
Henrique Rui M.,
Lopes Carlos,
Baltazar Fátima,
Ribeiro Daniela
Publication year - 2015
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.12481
Subject(s) - peroxisome , prostate cancer , malignant transformation , cancer research , cancer , biomarker , biology , prostate , monocarboxylate transporter , transporter , cancer cell , microbiology and biotechnology , biochemistry , gene , genetics
Abstract Previous studies on monocarboxylate transporters expression in prostate cancer ( PCa ) have shown that monocarboxylate transporter 2 ( MCT 2) was clearly overexpressed in prostate malignant glands, pointing it out as a putative biomarker for PCa . However, its localization and possible role in PCa cells remained unclear. In this study, we demonstrate that MCT 2 localizes mainly at peroxisomes in PCa cells and is able to take advantage of the peroxisomal transport machinery by interacting with Pex19. We have also shown an increase in MCT 2 expression from non‐malignant to malignant cells that was directly correlated with its peroxisomal localization. Upon analysis of the expression of several peroxisomal β‐oxidation proteins in PIN lesions and PCa cells from a large variety of human prostate samples, we suggest that MCT 2 presence at peroxisomes is related to an increase in β ‐oxidation levels which may be crucial for malignant transformation. Our results present novel evidence that may not only contribute to the study of PCa development mechanisms but also pinpoint novel targets for cancer therapy.